Systematic review of the management of atrial fibrillation in patients with heart failure

European Heart Journal

Volumn 21, Issue 8, 2000, Pages 614-632

  Khand, A U ^a   Rankin, A C ^a   Kaye, G C ^b   Cleland, J G F ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Atrial fibrillation; Evidence based cardiology; Heart failure; Systematic review

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM;

ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; SURVIVAL RATE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ACUTE DISEASE; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; CLINICAL TRIALS; DIGOXIN; DILTIAZEM; ELECTRIC COUNTERSHOCK; HEART FAILURE, CONGESTIVE; HUMANS; RETROSPECTIVE STUDIES;

EID: 0034124255     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1767     Document Type: Review

References (121)

1. Kannel WB, Abbott RD, Savage DD, Mcnamara PM. Epidemiological features of chronic atrial fibrillation. N Engl J Med. 306:1982;1018-1022.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy ET. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Mannitoba Follow-up study. Am J Med. 98:1995;466-484.
3. Onundarson PT, Thorgeirson G, Jonmundsson E, Sigfusson N, Hardarson TH. Chronic atrial fibrillation-epidemiological features and 14 year follow-up: a case control study. Eur Heart J. 8:1987;521-527.
4. Garg R, Yusuf S, Pouler DB, Francis GS. Congestive cardiac failure-pathophysiology and treatment. Epidemiology of congestive cardiac failure. 1993;. p. 9-25.
5. Jordaens L, Trouerbach J, Calle P. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 18:1997;643-648.
6. Swedberg K, Idanpaan Heikkila U, Remes J. Effects of enalapril on mortality in severe congestive heart failure. Results of the Coperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:1987;1429-1435.
7. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355.
8. Johnstone D, Limacher M, Rousseau M. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol. 70:1992;894-900.
9. Janse JM. Why does Atrial fibrillation occur? Eur Heart J. 18:1997;C12-8.
10. Isobe F, Schuessler RB, Mitsuno M. High atrial pressure directly affects the disposition of refractoriness and the inducibility of atrial fibrillation (Abstr). Circulation. 88:1993;326.
11. Van Den Berg MP, Tuinenberg AE, Crijns HJGM, Van Gelder IC, Gosselink ATM, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 77:1997;309-313.
12. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, Incidence, Prognosis, and Predisposing conditions For Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 82:1998;2N-9N.
13. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Int Med. 148:1988;2013-2016.
14. Opasich C, Febo O, Riccardi PG. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 78:1996;354-357.
15. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 69:1992;1570-1573.
16. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronically rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med. 85:1988;242-244.
17. Haiat R, Halphen C, Stoltz JP, Leroy G, Sousanna C. Atrial fibrillation: a cause of reversible cardiomyopathy. Ann Cardiol Angeiol. 36:1987;417-419.
18. Brill IC. Congestive cardiac failure arising from uncontrolled auricular fibrillation in the otherwise normal heart: follow-up notes on a previously reported case. Am J Med. 2:1947;544.
19. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med. 7:1949;478.
20. Pedersen OD, Bagger H, Torp-Pederson C. Trandolapril reduces incidence of atrial fibrillation following acute myocardial infarction. Circulation. 100:1999;376-380.
21. Van Den Berg MG, Crijns HJGM, Veldhuisen DJV. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Cardiac Failure. 1:1995;355-363.
22. Anonymous. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 92:1995;2764-2784.
23. Eur Heart J. 18:1997;649-654.
24. Galve E, Rius T, Ballester R. Intravenous Amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol. 27:1996;1079-1082.
25. Hou ZY, Chang MS, Chen CY. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur Heart J. 16:1995;521-528.
26. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pederson WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive cardiac failure. Am J Cardiol. 74:1994;884-889.
27. Andrivet P, Boubakri E, Dove PJ, Mach V, Ngoc CV. A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachyarrhythmia. Eur Heart J. 15:1994;1396-1402.
28. Kumar A. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. Southern Medical Journal. 89:1996;781-785.
29. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 81:1998;594-598.
30. Heywood JT, Graham B, Marais GE, Jutzy KR. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol. 67:1991;1150-1152.
31. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
32. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 27:1997;385-390.
33. Deedwania PC, Singh BN, Ellenbogen KA, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation. 98:1998;2574-2579.
34. Singh SN, Fletcher R, Fisher S. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
35. Van Gelder IC, Crijns HJGM, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 68:1991;41-46.
36. Tieleman RG, Gosselink ATM, Crijns HJGM, Van Gelder IC, Van Den Berg MG. Efficacy, safety and determinants of conversion of atrial fibrillation or flutter with oral amiodarone. Am J Cardiol. 79:1997;53-57.
37. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillege HL, Weisfield ACO, Lie KI. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 267:1992;3289-3293.
38. Mostow ND, Vrobel TR, Noon D, Rakita L. Rapid control of refractory atrial tacharrhythmia with high-dose oral amiodarone. Am Heart J. 120:1990;1356.
39. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Vijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or flutter. Am J Cardiol. 64:1989;1317-1321.
40. Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J. 37:1975;486-492.
41. Karlson BW, Torstensson I, Abjorn C, Jannson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. A placebo-controlled one-year follow up study. Eur Heart J. 9:1988;284-290.
42. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol. 63:1989;114-116.
43. Middlekauf HR, Stevenson WG, Saxon LA, Stevenson LW. Low dose amiodarone for atrial fibrillation in advanced heart failure restores sinus rhythm and improves functional capacity (Abstr). Circulation. 86:1992;I-808.
44. Crijns HJGM, Van Gelder IC, Van Gilst WH, Hillege HL, Gosselink ATM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Am J Cardiol. 68:1991;335-341.
45. Kudoh M. Clinical studies on long-term combined therapy of digitalis and xamoterol for patients with mild and moderate congestive heart failure accompanied by atrial fibrillation. Teikyo Med J. 16:1988;65-74.
46. Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest. 71:1977;592-596.
47. Cristodorescu R, Rosu D, Deutsch G, Verdes A, Luca C. The heart rate slowing effect of pindolol in patients with digitalis resistant atrial fibrillation and heart failure. Rev Roum Med-Med Int. 24:1986;207-215.
48. Maragno I, Santostasi G, Gaion RM, Trento M, Grion AM. Low and medium dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J. 116:1988;385-393.
49. Twidale N, Sutton K, Dooley A. Effects on cardiac performance of atrioventricular node catheter ablation using radio-frequency current for drug-refractory atrial arrythmias. PACE. 16:1993;1275-1284.
50. Edner M, Caidahl K, Bergfeldt L. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J. 74:1995;261-267.
51. Heinz G, Siostrzonek P, Kreiner G, Gossinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 69:1992;489-492.
52. Twidale N, Manda V, Nave K, Seal A. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am Heart J. 136:1998;647-657.
53. Brignole M, Gianfranchi L, Menozzi C. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 74:1994;242-246.
54. Brignole M, Menozzi C, Gianfranchi L. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. Circulation. 98:1998;953-960.
55. Cleland JGF, Cowburn PJ. Should all patients with atrial fibrillation recieve warfarin? Evidence from randomized clinical trials. Eur Heart J. 17:1996;674-681.
56. Jagasia DH, Williams B, Ezekowitz MD. Clinical implications of antiembolic trials in atrial fibrillation and role of transesophageal echocardiography in atrial fibrillation. Curr Opin Cardiol. 15:2000;58-63.
57. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobsen A. Antithrombotic therapy in atrial fibrillation. 4th ACCP Consensus Conference on Antithrombotic Therapy. Chest. 108:1995;352S-9S.
58. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS. Transoesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study. J Am Coll Cardiol. 25:1995;1354-1361.
59. Levy S, Breithardt G, Campbell RWF. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J. 19:1998;1294-1320.
60. Ravid S, Podrid PJ, Lampert S, Lown B. Congestive Heart Failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol. 14:1989;1326-1330.
61. Middlekauf HR, Stevenson WG, Stevenson LW. Antiarrhythmic drug therapy in 367 heart failure patients: Class 1 drugs but not amiodarone are associated with increased sudden death risk (Abstr). J Am Coll Cardiol. 17:1991;92A.
62. Rehnqvist N. Arrhythmias and their treatment in patients with heart failure. Am J Cardiol. 64:1989;61J-4J.
63. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Batinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomised, double-blind trial. Ann Int Med. 106:1987;593-596.
64. Boriani G, Bbiffi M, Cappuci A. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. Ann Int Med. 126:1997;621-625.
65. Kerr AJ, Simmonds MB, Stewart RAH. Influence of heart rate on stroke volume variability in atrial fibrillation in patients with normal and impaired left ventricular function. Am J Cardiol. 821:1999;496-500.
66. Cleland JGF, Freemantle N, Mcgowan J, Clark A. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure. Br Med J. 318:1999;824-825.
67. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: A drug whose time has gone? Ann Int Med. 114:1991;573-575.
68. Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of 'therapeutic' serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol. 35:1975;651-655.
69. Beasley R, Smith DA, Mchaffe DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J. 290:1985;570-576.
70. Garg R, Gorlin R, Smith T, Yusuf S. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
71. Yusuf S. Digoxin in heart failure: results of the recent Digoxin Investigation Group trial in the context of other treatments for heart failure. Eur Heart J. 18:1997;1685-1688.
72. Packer M, Lee WH, Medina N. Comparative negative inotropic effects of nifedipine and diltiazem in patients with severe left ventricular dysfunction (Abstr). Circulation. 72:1985;111-125.
73. Materne P, Legrand V, Vandormel M, Collignon P, Kulbertus HE. Haemodynamic effects of intravenous diltiazem with impaired left ventricular function. Am J Cardiol. 54:1984;733-737.
74. Walsh RW, Pane CR, Starling MR, O'Rourke RA. Beneficial haemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure. J Am Coll Cardiol. 3:1984;1044-1050.
75. Kullick DL, Mcintosh N, Campese VM. Central and renal haemodynamic effects and hormonal response to diltiazem in severe congestive cardiac failure. Am J Cardiol. 59:1987;1138-1143.
76. Goldstein RE, Boccuzzi SJ, Cruess D. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 83:1991;52-60.
77. Figulla HR, Gletzen F, Zeymer U. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: Results of the diltiazem in dilated cardiomyopathy trial. Circulation. 94:1996;346-352.
78. Liao YH. Interventional study of diltiazem in dilated cardiomyopathy: A report of multiple centre clinical trial in China. Chinese cooperative group of diltiazem intervention trial in dilated cardiomyopathy. Int J Cardiol. 64:1998;25-30.
79. Ang EL, Chan WL, Cleland JG. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J. 64:1990;256-260.
80. Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated cardiomyopathy (MDC) Trial Study Group. Lancet. 342:1993;1441-1446.
81. Anonymous. Effects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation. 92:1995;212-218.
82. Anonymous. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 90:1994;1765-1773.
83. Eichorn EJ, Lukas MA, Schusterman N. Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity (Abstr). Circulation. 98:1998;I-365.
84. Mcgowan J, Cleland JGF. Carvedilol in Heart Failure: Clinical Trials in Progress. Heart Fail Rev. 4:1999;89-95.
85. Schwartz A, Shen E, Morady F, Gillespie K, Scheinman M, Chatterjee K. Haemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J. 106:1983;848-855.
86. Middlekauf HR, Stevenson WG, Saxon LA, Stevenson LW. Amiodarone and Torsades de Pointes in patients with advanced heart failure. Am J Cardiol. 76:1995;499-502.
87. Hohnloser, SH, Klingenheben, T, Singh, BN, Amiodarone-associated proarrhythmic effects, Ann Intern Med, 121, 529, 35.
88. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transoesophageal echocardiograhic study. J Am Coll Cardiol. 25:1995;452-459.
89. Lown B. Electrical cardioversion of cardiac arrhythmia. Br Heart J. 29:1967;469-487.
90. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol. 78:1996;3-11.
91. Waktare JEP, Camm AJ. Atrial fibrillation begets trouble. Heart. 77:1997;393-394.
92. Van Gelder IC, Crijns HJGM, Lie KI. Anonymous; atrial fibrillation: a treatable disease? Characteristics of patients with atrial fibrillation and predictions of uneventful cardioversion. 1992;Kluwer Academic Publishers, Dordrecht. p. 67-86.
93. Cappuci A, Aschieri GQ, Villani F, Passerini F, Groppi A. Oral amiodarone increases efficacy of DC cardioversion in patients with chronic atrial fibrillation and organic heart disease. J Am Coll Cardiol. 29:1997;443A.
94. Weinberg BA, Miles WM, Klein LS. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J. 125:1993;109-121.
95. Hoffman BF, Bigger JT, Gilman AG, Rall TW, Nies AS, Taylor P. The pharmacological basis of therapeutics. Digitalis and allied cardiac glycosides. 1990;Pergamon Press, New York. p. 814-39.
96. Grande P, Sonne B, Pederson A. A controlled study of digoxin and quinidine in patients DC reverted from atrial fibrillation to sinus rhythm (Abstr). Circulation. 74:1986;11-101.
97. Hornestam B, Carlsson T, Falk L. Effects of intravenously administered digoxin in acute atrial fibrillation, compared to placebo (Abstr). Circulation. 92:1995;I-774.
98. Echt DS, Liebson PR, Mitchell LB. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 342:1991;781-788.
99. Lancet. 350:1997;1417-1424.
100. Julian DG, Camm AJ, Frangin G. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 349:1997;667-674.
101. Pedersen OD. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function: Atrial Fibrillation in the DIAMOND study (Abstr). Circulation. 98:1998;I-632.
102. Pritchett E, Durham NC, Page R. Azimilide treatment of atrial fibrillation (Abstr). Circulation. 98:1998;I-633.
103. Tuinenberg AE, Van Gelder IC. Heart failure during atrial fibrillation is related to the presence and severity of the underlying disease (Abstr). Circulation. 96:1997;I-76.
104. Zehender M, Faber T, Jeron A. Is conversion of atrial fibrillation the ultimate longterm goal? (Abstr). Circulation. 92:1995;I-775.
105. Geelen P, Brugada J, Andries E, Brugada P. Ventricular Fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. PACE. 20:1997;343-348.
106. Daoud E, Weiss R, Bahu M. Effect of irregular ventricular rhythm on cardiac output. Am J Cardiol. 78:1996;1433-1436.
107. Naccarelli GV, Luck JC, Wolbrette DL. Pacing therapy for congestive heart failure: is it ready for prime time? Curr Opin Cardiol. 14:1999;1-3.
108. Zile M, Blaustein A, Shimuzu G, Gaasch W. Right ventricular pacing reduces the rate of left ventricular relaxation and filling. J Am Coll Cardiol. 10:1987;702-709.
109. Harvey MN, Morady F. Radiofrequency catheter ablation for atrial fibrillation. Cor Art Dis. 6:1995;115-120.
110. Cox JL, Boineau JP, Scheussler SA, Kater KM, Lappas DG. Five-year experience with the maze procedure for atrial fibrillation. Ann Thorac Surg. 56:1993;814-824.
111. Daubert C, Mabo P, Berder V, Gras D, Leclerq C. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronisation. Eur J Cardiac Electrophysiol. 4:1995;35-44.
112. Timmermans C, Lau CP, Tse HF. Early experience with the metrix implantable defibrillator (Abstr). Eur Heart J. 18:1997;134.
113. Swartz JF, Pellersels G, Silvers J. A catheter-based curative approach to atrial fibrillation in humans (Abstr). Circulation. 90:1994;I-335.
114. Atwood JE, Myers J, Sullivan MJ. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J. 118:1989;913-918.
115. Ueshima K, Myers J, Morriss CK. The effect of cardioversion on exercise capacity in patients with atrial fibrillation. Am Heart J. 126:1993;1021-1024.
116. Gosselink ATM, Crijns HJGM, Van Den Berg MP. Functional capacity before and after cardioversion of atrial fibrillation. Br Heart J. 72:1994;161-166.
117. Gosselink ATM, Bijlsma EB, Landsman ML, Crijns HJGM, Lie KI. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation. A 2 year follow-up. Eur Heart J. 15:1994;1368-1372.
118. Kubac G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can J Cardiol. 8:1992;941-946.
119. Lundstrom T, Karlsson O. Improved ventilatory response to exercise after cardioversion of chronic atrial fibrillation to sinus rhythm. Chest. 102:1992;1017-1022.
120. Am J Cardiol. 79:1997;1198-1202.
121. Hohnloser SH, Kuck KH. Atrial Fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial. PACE. 20:1997;1989-1992.